<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612621</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-20-7346-UK-CTIL</org_study_id>
    <nct_id>NCT04612621</nct_id>
  </id_info>
  <brief_title>MILESTONE-CD -A Prospective Multiomic Inception Real -Life Study To Evaluate Predictors of Disease Outcomes &amp; respoNse to Biologic Treatment in Crohn's Disease</brief_title>
  <acronym>MILESTONE-CD</acronym>
  <official_title>MILESTONE-CD -A Prospective Multiomic Inception Real -Life Study To Evaluate Predictors of Disease Outcomes &amp; respoNse to Biologic Treatment in Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crohn's' disease (CD) is a lifelong-chronic inflammatory condition of the digestive tract. CD&#xD;
      frequently manifests during the 2nd or 3rd decade; prolonged disease duration frequently&#xD;
      results in major structural complications such as strictures and fistulae, leading to surgery&#xD;
      for control of complications in at least 30% of the patients. The course of disease is&#xD;
      extremely diverse, ranging from a very mild disease to a devastating and incapacitating&#xD;
      course. The burden of inflammatory bowel disease is growing each disease, reaching 400&#xD;
      billion USD for lifetime in US. In Israel, there are currently over 50000 IBD patients, with&#xD;
      one of the highest incidences in the word, multiple treatment modalities and medications are&#xD;
      available for Crohn's disease, however the efficacy is limited and the costs- very high.&#xD;
      Furthermore, long-term exposure to some of the therapeutic agents poses an increased risk of&#xD;
      infections and cancer.&#xD;
&#xD;
      Some of the major challenges in IBD include prediction of disease course (some patients will&#xD;
      require early and aggressive treatment while others may just need observation and follow-up),&#xD;
      and treatment personalization (right drug for the right patient at the right time).&#xD;
      Unfortunately, individualized predictors of disease course and response to treatment are&#xD;
      currently very limited. Some clues can be derived from imaging and endoscopy data,&#xD;
      transcriptomics, genomic and microbiome, however those are still very premature and&#xD;
      impractical. Moreover, large-scale studies with sophisticated predictive models that&#xD;
      incorporate multilayered and multilayered clinical and omic data are severely lacking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Goal:&#xD;
&#xD;
      Create comprehensive patient-multiomic profile&#xD;
      (PRO-Visualosome-microbiome-transcriptome-pharmacokineticome) to develop algorithm-based&#xD;
      personalized IBD therapy&#xD;
&#xD;
      Design Prospective observational cohort study.&#xD;
&#xD;
      Study aim To detect predictors of response to biologics using a layered multiomic approach&#xD;
&#xD;
      Cohort size Up to 140 patients in 2 years&#xD;
&#xD;
      Study duration -Patients will be followed up to 2 years (possible extension) or until&#xD;
      treatment discontinuation or intestinal surgery&#xD;
&#xD;
      Study procedures All study procedures will be performed for the purpose of the study&#xD;
&#xD;
      Baseline&#xD;
&#xD;
      Disease activity using Harvey Bradshaw score at all timepoints and visits&#xD;
&#xD;
        -  baseline PROS -PROMIS10/SIBDQ/IBD control/PRO2 using DATOS app&#xD;
&#xD;
        -  colonoscopy with Intestinal biopsies&#xD;
&#xD;
        -  Blood for transcriptomics&#xD;
&#xD;
        -  Blood/serum for serum and cellular markers&#xD;
&#xD;
        -  Stool for microbiome/metabolomics (if colonoscopy done- a rectal swab during colonoscopy&#xD;
           will be performed)&#xD;
&#xD;
        -  Pillcam CD following patency capsule - if failed patients still will be included and&#xD;
           continue follow- up without capsule endoscopy&#xD;
&#xD;
        -  MRE&#xD;
&#xD;
        -  IUS&#xD;
&#xD;
        -  Fecal calprotectin home kit with CALPROSMART&#xD;
&#xD;
        -  Basic chemistry&#xD;
&#xD;
        -  Joint US (if joint symptoms) Repeated assessment -every month&#xD;
&#xD;
        -  PROMIS10/SIBDQ/IBD control/-via DATOS app (during the first 14-16 weeks- PRO2 will be&#xD;
           evaluated weekly) Continuous monitoring (mobile device via DATOS app)&#xD;
&#xD;
      First follow-up visit (12-14 weeks)&#xD;
&#xD;
        -  Calprotectin&#xD;
&#xD;
        -  Microbiome&#xD;
&#xD;
        -  Blood for transcriptomics&#xD;
&#xD;
        -  Blood/serum for serum and cellular markers, drug levels, CRP&#xD;
&#xD;
      Every 3 months&#xD;
&#xD;
      - Home calprotectin (Calprosmart) +microbiome&#xD;
&#xD;
      Every 6 months&#xD;
&#xD;
        -  Clinic visit&#xD;
&#xD;
        -  Pillcam CD&#xD;
&#xD;
        -  IUS&#xD;
&#xD;
        -  Blood for transcriptomics&#xD;
&#xD;
        -  Blood/serum for serum and cellular markers, drug levels, CRP&#xD;
&#xD;
        -  Calprotectin (home +ELISA) + microbiome&#xD;
&#xD;
      Upon failure (need to switch medication -defined by treating physician) or end of study&#xD;
&#xD;
        -  Clinic visit&#xD;
&#xD;
        -  Calprotectin *Home +ELISA)&#xD;
&#xD;
        -  Microbiome&#xD;
&#xD;
        -  Serum for transriptomics, metabolomics&#xD;
&#xD;
        -  Blood/serum for serum and cellular markers, drug levels, CRP&#xD;
&#xD;
        -  Repeat Pillcam CD (if not done within 6 months)&#xD;
&#xD;
        -  Repeat IUS +thermal imaging (if not done within 6 months)&#xD;
&#xD;
        -  MRE&#xD;
&#xD;
             -  Drug levels will be done at every infusion for IV drugs and every 6 months for SC&#xD;
                biologics and at the end of induction (week 8-16)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All enrolled patients will undergo similar interventions</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>failure of first biologic</measure>
    <time_frame>2 years</time_frame>
    <description>cessation or switch of first biologic as per decision of the treating physician (documentation of change of therapy from the first biologic for any reason)</description>
  </primary_outcome>
  <enrollment type="Anticipated">149</enrollment>
  <condition>Crohn Disease of Intestine</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>combination of diagnostic tests</intervention_name>
    <description>capsule endoscopy, MRE , intestinal ultrasound, fecal microbiota, blood and serum biomarkers as described</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Crohn's disease&#xD;
&#xD;
          -  Start of first-line biological therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous biologic therapy&#xD;
&#xD;
          -  Previous surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miri Lipkin, BSC</last_name>
      <phone>03507079</phone>
      <email>Miri.LipkinBony@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

